Tanas Yousef, Gasper Grace, Tanas Julie, Swed Sarya, De Sario Velasquez Gioacchino
Institute for Reconstructive Surgery, Houston Methodist Hospital, Weill Cornell Medicine, Houston, TX, USA.
School of Engineering Medicine, Texas A&M, Houston, TX, USA.
Syst Rev. 2025 Jul 30;14(1):157. doi: 10.1186/s13643-025-02915-y.
Acellular dermal matrices (ADMs) have become popularly used in implant-based breast reconstruction (IBBR) due to their potential to decrease the risk of implant complications such as capsular contracture and malposition. AlloDerm and DermACELL are two of the most commonly used human ADMs, each processed differently to enhance sterility and biocompatibility. Despite their widespread use, the comparative effectiveness and safety of these ADMs remain debatable among plastic surgeons, with conflicting evidence in the literature regarding their complication profiles. This systematic review and meta-analysis aims to evaluate the clinical outcomes associated with AlloDerm versus DermACELL in breast reconstruction.
This review will follow the methodological guidance of the Cochrane Handbook for Systematic Reviews of Interventions. The database search will be conducted using MEDLINE (PubMed), Scopus, Web of Science, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Clinicaltrials.org targeting studies from inception to search date. Studies will be screened using inclusion and exclusion criteria and data extracted into a spreadsheet. Screening, extraction, and risk-of-bias assessments will be performed independently by two reviewers and discrepancies resolved by a third independent reviewer. Primary outcomes include complication rates (e.g., capsular contracture, infection, implant malposition), patient-reported satisfaction (BREAST-Q), and drain time. Data analysis and meta-analysis will be performed using Microsoft Excel and Review Manager 5.4 software. Heterogeneity will be assessed using the I statistic. A random-effects model will be applied in cases of significant heterogeneity followed by a sensitivity analysis. This review will be reported in accordance with the PRISMA 2020 checklist.
With the increasing use of ADMs in IBBR, it is important that surgeons have adequate evidence available to assist operative decision-making. This meta-analysis will help surgeons determine whether one ADM is better than the other. This could potentially minimize the risk of patient complications, improve patient satisfaction, and decrease unnecessary hospital readmissions or reoperations due to avoidable complications, thereby decreasing healthcare costs.
PROSPERO CRD42024542928.
脱细胞真皮基质(ADM)因其有可能降低植入相关并发症(如包膜挛缩和移位)的风险,已广泛应用于基于植入物的乳房重建(IBBR)。AlloDerm和DermACELL是两种最常用的人源ADM,每种产品的加工方式不同,以提高无菌性和生物相容性。尽管它们被广泛使用,但这些ADM的相对有效性和安全性在整形外科医生中仍存在争议,文献中关于它们并发症情况的证据相互矛盾。本系统评价和荟萃分析旨在评估在乳房重建中使用AlloDerm与DermACELL相关的临床结局。
本评价将遵循Cochrane干预措施系统评价手册的方法学指导。将使用MEDLINE(PubMed)、Scopus、Web of Science、Cochrane对照试验中央注册库、Cochrane系统评价数据库和Clinicaltrials.org进行数据库检索,检索从开始到检索日期的研究。将使用纳入和排除标准筛选研究,并将数据提取到电子表格中。筛选、提取和偏倚风险评估将由两名审阅者独立进行,分歧由第三名独立审阅者解决。主要结局包括并发症发生率(如包膜挛缩、感染、植入物移位)、患者报告的满意度(BREAST-Q)和引流时间。将使用Microsoft Excel和Review Manager 5.4软件进行数据分析和荟萃分析。将使用I统计量评估异质性。在存在显著异质性的情况下,将应用随机效应模型,随后进行敏感性分析。本评价将按照PRISMA 2020清单进行报告。
随着ADM在IBBR中的使用增加,外科医生有足够的证据来辅助手术决策非常重要。这项荟萃分析将帮助外科医生确定一种ADM是否优于另一种。这可能会潜在地降低患者并发症的风险,提高患者满意度,并减少由于可避免的并发症导致的不必要的住院再入院或再次手术,从而降低医疗成本。
PROSPERO CRD42024542928。